Biomarker ID | 1724 |
PMID | 30777394 |
Year | 2019 |
Biomarker | CRIP3 |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Urine |
Subjects | Humans |
Regulation | Upregulated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | OR: 1.079 (95% CI: 1.013-1.15) |
Effect on Pathways | Pathway include: ROR1 human kinase ARCHS4 coexpression |
Experiment | Reclassification (Progression Vs No Progression) |
Type of Biomarker | Prognostic |
Cohort | 109 patients with Prostate Cancer were selected for the study. Out of which 23 patients were reclassified: |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.017 |
Method Used | qPCR-based MethyLight assay |
Clinical | No |
Remarks | Patients were considered reclassified if they experienced Gleason Grade increase on repeat biopsy |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |